Breast Cancer Immunotherapy Evaluation

Breast cancer cells (BT474 cell line, representative of HER2 + breast cancer subtype) were co-cultured in 3D biomimetic collagen gels, within microfluidic devices, with immune cells (PBMCs, peripheral blood mononuclear cells from healthy donors), without or with the addition of targeted immunotherapy, the trastuzumab (brand name Herceptin). For details, see the original biological publication^{12 (link)}. In this use case, we demonstrated how deep features’ discrimination capability of the effect of targeted immunotherapy in breast tumors is influenced by image alterations and compared results with those achieved using standard features selection approaches using diverse deep learning architectures.